Capital Fund Management (CFM)
NBIX icon

Capital Fund Management (CFM)’s Neurocrine Biosciences NBIX Stock Holding History

Capital Fund Management (CFM)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,100
Closed -$1.29M – 1957
2018
Q4 		$1.29M Sell
18,100
-20,900
-54% -$2M 0.01% 1016
2018
Q3 		$4.79M Buy
+39,000
New +$4.42M 0.03% 782
2018
Q2 		– Sell
-78,200
Closed -$6.49M – 2188
2018
Q1 		$6.49M Buy
+78,200
New +$6.6M 0.04% 590

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s NBIX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Neurocrine Biosciences (NBIX) stake by 87% in Q1 2026, buying an estimated $9.22M and bringing the position to 149,631 shares worth $19.7M. The position accounts for 0.09% of the portfolio, ranked #314.

Capital Fund Management (CFM) first reported a position in NBIX in Q2 2015 and has held it in 25 quarters since. The position peaked at $25.6M in Q2 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Capital Fund Management (CFM) held 149,631 shares of Neurocrine Biosciences worth $19.7M as of Q1 2026.
  • Capital Fund Management (CFM) bought 69,506 Neurocrine Biosciences shares in Q1 2026, an estimated $9.22M.
  • Neurocrine Biosciences made up 0.09% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #314 holding.
  • Capital Fund Management (CFM) first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 25 quarters since.
  • Capital Fund Management (CFM)'s Neurocrine Biosciences position peaked at $25.6M in Q2 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.